Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update
The live call may be accessed by dialing 844-358-8763 for domestic callers, or 703-736-7375 for international callers, and use the conference ID # 2899958. The webcast will be made available on Cidara’s website at www.cidara.com under the News and Events tab in the Investors section. Following the live audio webcast, a replay will be available on Cidara's website for approximately 30 days.
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to
Westwicke Partners, LLC
Sam Brown Inc.